LLY vs PLX

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Protalix (PLX) continues to exhibit strong potential for 10x growth, building on its recent financial turnaround. The stellar Q1 2026 performance, with $18.3 million net income and $0.22 GAAP EPS (as noted in prior analysis and consistent with current P/E), substantially de-risks profitability concerns. The reaffirmed 2026 revenue guidance of $78–$83 million, backed by the $25 million Chiesi miles...